Editorial Comment

Abstract

The authors compared prostate-specific antigen (PSA) levels before and after simple prostatectomy between those who were and were not diagnosed with prostate cancer (CaP). The data presented provide the practicing urologist with helpful information for assessing the risk of CaP after simple prostatectomy using PSA and PSA changes. ReplyUrologyVol. 74Issue 1PreviewWe agree with the notion initially presented by Dr. Walsh that the utility of prostate-specific antigen (PSA) measurement after undergoing surgical intervention for the treatment of benign prostatic hyperplasia (BPH) might represent a more sensitive tool to distinguish the presence of prostate cancer (CaP) because of the removal of confounding benign adenoma. However, different surgical procedures differ in their efficacy in removing adenoma. Thus, each procedure used for the treatment of BPH might have its own unique postoperative PSA nadir secondary to the amount of residual benign disease. Full-Text PDF Postoperative PSA and PSA Velocity Identify Presence of Prostate Cancer After Various Surgical Interventions for Benign Prostatic HyperplasiaUrologyVol. 74Issue 1PreviewTo determine whether prostate-specific antigen (PSA) values can distinguish those with prostate cancer (CaP) from those with histologic benign prostatic hyperplasia (BPH) only after surgical intervention. Prostatic adenoma inevitably remains after BPH surgery; therefore, patients remain at risk of developing CaP. Although the PSA level can be used for CaP screening in this population, it might be influenced by the efficacies of different BPH procedures. Full-Text PDF